Olaparib-mediated Enhancement of 5-fluorouracil Cytotoxicity in Mismatch Repair Deficient Colorectal Cancer Cells

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Apr 23

PMID 33888065

Citations 6

Authors

Helena de Castro E Gloria

Laura Jesuino Nogueira

Patricia Bencke Grudzinski

Paola Victoria da Costa Ghignatti

Temenouga Nikolova Guecheva

Natalia Motta Leguisamo

Jenifer Saffi

Affiliations

Soon will be listed here.

Abstract

Background: The advances in colorectal cancer (CRC) treatment include the identification of deficiencies in Mismatch Repair (MMR) pathway to predict the benefit of adjuvant 5-fluorouracil (5-FU) and oxaliplatin for stage II CRC and immunotherapy. Defective MMR contributes to chemoresistance in CRC. A growing body of evidence supports the role of Poly-(ADP-ribose) polymerase (PARP) inhibitors, such as Olaparib, in the treatment of different subsets of cancer beyond the tumors with homologous recombination deficiencies. In this work we evaluated the effect of Olaparib on 5-FU cytotoxicity in MMR-deficient and proficient CRC cells and the mechanisms involved.

Methods: Human colon cancer cell lines, proficient (HT29) and deficient (HCT116) in MMR, were treated with 5-FU and Olaparib. Cytotoxicity was assessed by MTT and clonogenic assays, apoptosis induction and cell cycle progression by flow cytometry, DNA damage by comet assay. Adhesion and transwell migration assays were also performed.

Results: Our results showed enhancement of the 5-FU citotoxicity by Olaparib in MMR-deficient HCT116 colon cancer cells. Moreover, the combined treatment with Olaparib and 5-FU induced G2/M arrest, apoptosis and polyploidy in these cells. In MMR proficient HT29 cells, the Olaparib alone reduced clonogenic survival, induced DNA damage accumulation and decreased the adhesion and migration capacities.

Conclusion: Our results suggest benefits of Olaparib inclusion in CRC treatment, as combination with 5-FU for MMR deficient CRC and as monotherapy for MMR proficient CRC. Thus, combined therapy with Olaparib could be a strategy to overcome 5-FU chemotherapeutic resistance in MMR-deficient CRC.

Citing Articles

PARP Inhibitors in Colorectal Malignancies: A 2023 Update.

Skouteris N, Papageorgiou G Rev Recent Clin Trials. 2023; 19(2):101-108.

PMID: 38058097 DOI: 10.2174/0115748871260815231116060817.

Research progress of traditional Chinese medicine as sensitizer in reversing chemoresistance of colorectal cancer.

Lin X, Yang X, Yang Y, Zhang H, Huang X Front Oncol. 2023; 13:1132141.

PMID: 36994201 PMC: 10040588. DOI: 10.3389/fonc.2023.1132141.

Identification of an m6A-Related Long Noncoding RNA Risk Model for Predicting Prognosis and Directing Treatments in Patients With Colon Adenocarcinoma.

Liao W, Long J, Li Y, Xie F, Xun Z, Wang Y Front Cell Dev Biol. 2022; 10:910749.

PMID: 35912098 PMC: 9326028. DOI: 10.3389/fcell.2022.910749.

Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer.

Papageorgiou G, Fergadis E, Skouteris N, Christakos E, Tsakatikas S, Lianos E Front Oncol. 2022; 11:788809.

PMID: 35004311 PMC: 8728007. DOI: 10.3389/fonc.2021.788809.

Peritoneal metastasis of colorectal cancer (pmCRC): identification of predictive molecular signatures by a novel preclinical platform of matching pmCRC PDX/PD3D models.

Dahlmann M, Gambara G, Brzezicha B, Popp O, Pachmayr E, Wedeken L Mol Cancer. 2021; 20(1):129.

PMID: 34670579 PMC: 8529724. DOI: 10.1186/s12943-021-01430-7.

References

Maya-Mendoza A, Moudry P, Merchut-Maya J, Lee M, Strauss R, Bartek J . High speed of fork progression induces DNA replication stress and genomic instability. Nature. 2018; 559(7713):279-284. DOI: 10.1038/s41586-018-0261-5. View

Park J, Huang S, Tougeron D, Sinicrope F . MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells. PLoS One. 2013; 8(5):e65369. PMC: 3665625. DOI: 10.1371/journal.pone.0065369. View

Hammond W, Swaika A, Mody K . Pharmacologic resistance in colorectal cancer: a review. Ther Adv Med Oncol. 2016; 8(1):57-84. PMC: 4699262. DOI: 10.1177/1758834015614530. View

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012; 366(15):1382-92. DOI: 10.1056/NEJMoa1105535. View

Fearon E . Molecular genetics of colorectal cancer. Annu Rev Pathol. 2010; 6:479-507. DOI: 10.1146/annurev-pathol-011110-130235. View

Williams S, Kuznicki A, Andrade P, Dolinski B, Elbi C, OHagan R . Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status. Cancer Cell Int. 2015; 15(1):14. PMC: 4326439. DOI: 10.1186/s12935-015-0162-8. View

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

Tentori L, Muzi A, Dorio A, Dolci S, Campolo F, Vernole P . MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. Cancer Chemother Pharmacol. 2013; 72(1):117-25. DOI: 10.1007/s00280-013-2175-0. View

Shelton J, Waxweiler T, Landry J, Gao H, Xu Y, Wang L . In vitro and in vivo enhancement of chemoradiation using the oral PARP inhibitor ABT-888 in colorectal cancer cells. Int J Radiat Oncol Biol Phys. 2013; 86(3):469-76. DOI: 10.1016/j.ijrobp.2013.02.015. View

10.

Hassen S, Ali A, Kilaparty S, Al-Anbaky Q, Majeed W, Boman B . Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines. Mol Cell Biochem. 2016; 412(1-2):297-305. DOI: 10.1007/s11010-015-2636-3. View

11.

SenGupta T, Torgersen M, Kassahun H, Vellai T, Simonsen A, Nilsen H . Base excision repair AP endonucleases and mismatch repair act together to induce checkpoint-mediated autophagy. Nat Commun. 2013; 4:2674. PMC: 3826653. DOI: 10.1038/ncomms3674. View

12.

Liao H, Ji F, Helleday T, Ying S . Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments. EMBO Rep. 2018; 19(9). PMC: 6123652. DOI: 10.15252/embr.201846263. View

13.

Arena S, Corti G, Durinikova E, Montone M, Reilly N, Russo M . A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clin Cancer Res. 2019; 26(6):1372-1384. DOI: 10.1158/1078-0432.CCR-19-2409. View

14.

Lord C, Ashworth A . PARP inhibitors: Synthetic lethality in the clinic. Science. 2017; 355(6330):1152-1158. PMC: 6175050. DOI: 10.1126/science.aam7344. View

15.

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

16.

Sargent D, Marsoni S, Monges G, Thibodeau S, Labianca R, Hamilton S . Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010; 28(20):3219-26. PMC: 2903323. DOI: 10.1200/JCO.2009.27.1825. View

17.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

18.

Takahashi M, Koi M, Balaguer F, Boland C, Goel A . MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor. J Biol Chem. 2011; 286(14):12157-65. PMC: 3069420. DOI: 10.1074/jbc.M110.198804. View

19.

Punt C, Koopman M, Vermeulen L . From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2016; 14(4):235-246. DOI: 10.1038/nrclinonc.2016.171. View

20.

Iwaizumi M, Tseng-Rogenski S, Carethers J . DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells. Cancer Biol Ther. 2011; 12(8):756-64. PMC: 3367669. DOI: 10.4161/cbt.12.8.17169. View